While there are now a multitude of unique psoriatic arthritis (PsA) therapies to choose from, many patients with PsA still fail to achieve the best possible long-term outcomes. These failures are in part due to a lack of understanding regarding the available targeted PsA therapies and how they address the underlying disease pathology (e.g. the central role of IL-17 in the etiology of PsA). In addition, some clinicians may not yet recognize the impacts different PsA disease domains have on patient quality of life.
This CME activity, “Understanding the Rationale for Newer IL-17-Targeted Psoriatic Arthritis Therapies: Essentials for Clinicians,” will help participants recognize and understand the role of IL-17 in the pathophysiology of PsA. The education will review relevant clinical-trial data and explore all the potential uses of already-approved IL-17 inhibitors, as well as novel investigational therapies. Expert faculty will also explore the influence of the various PsA disease domains on patient well-being.